Injectable Osteogenic Polymer Matrix for Localized Bone Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for growing bone in specific locations are invasive, costly, and often result in complications such as bone resorption, prolonged recovery times, and limited effectiveness in treating bone defects and diseases affecting millions of Americans, including craniotomy resorption, periodontal disease, osteoporosis, and joint replacements.
Innovation Solution
A formulation combining an osteogenic compound, such as prostaglandin (PGE), with a biodegradable delivery vehicle like hyaluronic acid or poly-glutamic acid matrix, allowing for site-specific bone growth through injection or implantation, minimizing invasive procedures and promoting localized bone healing without ectopic ossification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bone grafting methods (autografts, metal plates, hydroxyapatite cement) are used for cranial defects, then bone replacement or structural support is achieved, but bone resorption occurs and invasive procedures are required
Solution Approach 1:
The patent uses a biodegradable polymer matrix as an intermediary carrier to deliver osteogenic compounds (BMPs, growth factors, or bone marrow cells) to the defect site. This intermediary system enables controlled release of osteoinductive agents that stimulate native bone formation without causing resorption, resolving the contradiction between achieving reliable bone growth and avoiding harmful resorption effects
Solution Approach 2:
The patent changes the chemical and physical parameters of the treatment by using biodegradable polymers with specific degradation rates and osteogenic compounds with controlled release kinetics. This parameter optimization enables sustained osteoinduction while preventing bone resorption, achieving reliable bone regeneration without the harmful effects of traditional materials
2Reliability
If invasive surgical procedures are used for bone repair, then structural support and bone growth are achieved, but recovery time is prolonged and morbidity increases
Solution Approach 1:
The patent replaces mechanical bone grafting and rigid fixation systems with a minimally invasive injectable or implantable polymer matrix delivery system. This substitution allows osteogenic compounds to be delivered through small incisions rather than large surgical openings, achieving effective bone repair while dramatically reducing surgical trauma and recovery time
3Reliability
If BMPs are used as osteogenic compounds, then bone growth is induced, but ectopic ossification occurs causing complications
Solution Approach 1:
The patent applies osteogenic compounds locally at the bone defect site through a targeted polymer matrix delivery system. The local concentration control and site-specific delivery prevent systemic or off-target effects that cause ectopic ossification, while maintaining high osteogenic effectiveness at the intended location through localized release of BMPs or growth factors
4Reliability
If current bone treatment methods are used, then structural support is provided, but treatment costs are high and healthcare burden increases
Solution Approach 1:
The patent uses biodegradable polymer matrices that naturally degrade and are absorbed by the body over time, eliminating the need for expensive secondary removal surgeries required by metal plates and other non-resorbable materials. The biodegradable carriers provide effective bone treatment while reducing overall treatment costs through automatic resorption and reduced surgical intervention requirements
Data Source
AI summary
Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.